TARA Company Profile and Key Details

Protara Therapeutics, Inc. (NASDAQ:TARA) closed at $5.77 USD, losing -$0.19 (-3.19%) from the previous close of $5.96. The stock is currently mid-range between its 52-week high and low $2.77 and $7.82. With a market capitalization of about $222.66 million, Protara Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.39). Key stats such as the average daily volume over the past year has been around 1.15 million shares, in line with its 52-week average. Headquartered in New York City, NY, Protara Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jesse Shefferman, the company employs approximately 28 people and listed since October 22, 2014. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.

TARA has shown mixed momentum, gaining 6.87% over the past week and 2.0% over the past quarter, though year-to-date performance is up 5.07%. Short-term trend indicators are bearishly aligned (SMA20 -12.58%, SMA50 -3.56%, SMA200 27.5%). The stock’s 14-day RSI is 43.31 (neutral), while the ATR of 0.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -26.21% below its high and over 108.3% above its low. Average 10-day trading volume of 1.94 million shares is significantly above the 3-month average of 1.14 million, indicating heightened recent market interest.

Protara Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.69. This means the shares are trading below this model’s fair value.

Protara Therapeutics, Inc. generated EPS of -$1.44 over the past year. Five-year average earnings growth is 55.31%. Wall Street analysts project EPS growth of 8.1% annually over the next five years. The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.33. Next year's EPS is expected at -$7.50. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $23.00. The high target offers 315.94% upside. The low target suggests 298.61% downside. The mean target is $23.20. This offers 302.08% upside. Protara Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 10, 2025, missed forecasts by -19.58%. The prior quarter beat by -18.6%. Over the last six quarters, Apple has recorded several small beats. These include -45.12% in August 06, 2024.

Protara Therapeutics, Inc. has 38.58 million shares outstanding. The public float is 35.46 million shares, elevated short interest at 7.37% of float. This equals 2.77 million shares. The short ratio is 13.64 days. Institutional investors hold 53.28% of the float. Insiders own 2.04%. Shefferman Jesse holds 879.44 thousand shares, Marshall Randall has 585.60 thousand shares and BESHAR LUKE M has 198.00 thousand shares.

Protara Therapeutics, Inc. (NASDAQ:TARA) shares are flat 5.07% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Protara Therapeutics, Inc. trading at a premium to the broader market with a P/E of -4.65. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $28.56, suggesting 394.97% upside. Our AI forecast model points to short-term strength (9.71% over two weeks), a medium-term rise (50.26% over three months), and a longer-term gain (388.91% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Protara Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.71%, with price expected at $6.33 by March 12, 2026, within a range of $5.66 to $7.04 3-Month Outlook: Projected rise of 50.26%, reaching $8.67 by May 27, 2026, with a range of $7.82 to $9.51. 1-Year Outlook: Projected gain of 388.91%, with price at $28.21 by February 26, 2027, within a range of $30.98 to $32.68.

Protara Therapeutics, Inc. trades at a P/E ratio of -4.65, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.86 suggesting the stock is closer to book value. The P/FCF stands at -4.61, also below market averages.